Merz Aesthetics Announces FDA Approval of Xeomin (incobotulinumtoxinA) as the First and Only U.S. Neurotoxin for the Simultaneous Treatment of Upper Facial Lines
Merz Aesthetics, the world’s largest dedicated medical aesthetics business, announced that the U.S. Food and Drug Administration (FDA) approved Xeomin (incobotulinumtoxinA) as the first and only neurotoxin for the simultaneous treatment of upper facial lines – forehead lines, frown lines and crow’s feet.
First approved in 2011, Xeomin was indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, or frown lines. This new upper facial lines FDA approval adds the indication for the treatment of horizontal forehead lines and lateral canthal lines, or crow’s feet, in addition to the previous frown lines indication.
“Xeomin is the first and only FDA-approved neurotoxin for the simultaneous treatment of upper facial lines (forehead lines, frown lines and crow’s feet lines),” said Samantha Kerr, PhD, Chief Scientific Officer, Merz Aesthetics, in a press release. “This new indication for Xeomin proves we are moving the needle within the toxin space and meeting the needs of our consumers as it comes to efficacy and results, while containing only the essential ingredients needed for treatment.”
Xeomin is now indicated for the temporary improvement in the appearance of moderate to severe upper facial lines. The total recommended Xeomin dose for treatment is 20 units for glabellar frown lines, 20 units for horizontal forehead lines and 24 units for the crow’s feet for a total of 64 units.
Read more at Business Wire >>
